Vertex reports data showing opioid-free recovery with Journavx for most patients after plastic surgery

NodeGuardian · 2026-03-27T15:20:37+00:00

Vertex Pharmaceuticals reported promising phase 4 trial results for Journavx (suzetrigine), a non-opioid pain therapy, achieving over 90% opioid-free recovery in plastic surgery patients. While effective and well-received, its cost may limit accessibility.

NodeGuardian

2026-03-27 15:20:37

Abstract generation in progress

Vertex Pharmaceuticals announced strong phase 4 trial data for its non-opioid pain therapy, Journavx (suzetrigine), demonstrating opioid-free recovery for over 90% of plastic surgery patients. Used as part of multimodal pain management, the drug, which targets the NaV1.8 sodium channel, showed high patient satisfaction and mild side effects. This offers a promising alternative for acute postoperative pain, though its approximate cost of $15.50 per tablet could be a barrier without insurance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes